These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 9230149)

  • 1. Plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1 are correlated with the presence of transplant coronary artery disease in cardiac transplant recipients.
    Warshofsky MK; Wasserman HS; Wang W; Teng P; Sciacca R; Apfelbaum M; Schwartz A; Michler RE; Mancini DM; Cannon PJ; Rabbani LE
    Am J Cardiol; 1997 Jul; 80(2):145-9. PubMed ID: 9230149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated plasma tissue plasminogen activator and anti-THP-1 antibodies are independently associated with decreased graft survival in cardiac transplant recipients.
    Warshofsky MK; Dominguez M; Eisenberg MS; Wasserman HS; Sciacca R; Wang W; Simon AD; Morse JH; Schwartz A; Anglés-Cano E; Rabbani LE
    Am J Cardiol; 2001 Jul; 88(1):30-4. PubMed ID: 11423054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
    Wiman B; Andersson T; Hallqvist J; Reuterwall C; Ahlbom A; deFaire U
    Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):2019-23. PubMed ID: 10938026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with unstable angina and non-st-segment elevation myocardial infarction.
    Gyöngyösi M; Glogar D; Weidinger F; Domanovits H; Laggner A; Wojta J; Zorn G; Iordanova N; Huber K
    Am Heart J; 2004 Jan; 147(1):158-64. PubMed ID: 14691435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Changes in coagulation and fibrinolysis in the patients with coronary heart disease in acute period and effect of drug intervention].
    Jia XQ; Dong CM; Qin J; Zhang L
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2012 Apr; 24(4):225-8. PubMed ID: 22464576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High PAI activity with correlation to triglyceride and HDL cholesterol values in patients with coronary artery disease with no difference in survivors of myocardial infarction.
    Ihnken K; Speiser W; Ruf W; Thiel W; Schlepper M; Müller-Berghaus G
    Ann Hematol; 1993 Nov; 67(5):237-44. PubMed ID: 8241347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Lp(a) and t-PA-PAI-1 complex levels in coronary heart disease.
    Süer S; Ulutin T; Sönmez H; Kökoğlu E; Uçişik N; Bayram C; Sultuybek G
    Thromb Res; 1996 Jul; 83(1):77-85. PubMed ID: 8837306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dehydroepiandrosterone therapy in men with angiographically verified coronary heart disease: the effects on plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) and fibrinogen plasma concentrations].
    Rabijewski M; Zgliczyński W
    Endokrynol Pol; 2007; 58(3):213-9. PubMed ID: 17940987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percutaneous interventions alter the hemostatic profile of patients with unstable versus stable angina.
    Yazdani S; Simon AD; Kovar L; Wang W; Schwartz A; Rabbani LE
    J Am Coll Cardiol; 1997 Nov; 30(5):1284-7. PubMed ID: 9350928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in the fibrinolytic system components during acute myocardial infarction.
    Ioannidou-Papayannaki E; Lefkos N; Boudonas G; Efthimiadis A; Psirropoulos D; Vogas V; Papadopoulos I; Klonizakis I
    Acta Cardiol; 2000 Aug; 55(4):247-53. PubMed ID: 11041123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: biochemical correlations and role as independent predictors of coronary artery stenosis.
    Segarra A; Chacón P; Martinez-Eyarre C; Argelaguer X; Vila J; Ruiz P; Fort J; Bartolomé J; Camps J; Moliner E; Pelegrí A; Marco F; Olmos A; Piera L
    J Am Soc Nephrol; 2001 Jun; 12(6):1255-1263. PubMed ID: 11373350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial).
    McBane RD; Hardison RM; Sobel BE;
    Am J Cardiol; 2010 Jan; 105(1):17-24. PubMed ID: 20102884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinolytic and inflammatory processes in pleural effusions.
    Philip-Joët F; Alessi MC; Philip-Joët C; Aillaud M; Barriere JR; Arnaud A; Juhan-Vague I
    Eur Respir J; 1995 Aug; 8(8):1352-6. PubMed ID: 7489803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Is slow coronary flow related with inflammation and procoagulant state?].
    Yazici M; Aksakal E; Demircan S; Sahin M; Sağkan O
    Anadolu Kardiyol Derg; 2005 Mar; 5(1):3-7. PubMed ID: 15755693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease.
    Lahlou-Laforet K; Alhenc-Gelas M; Pornin M; Bydlowski S; Seigneur E; Benetos A; Kierzin JM; Scarabin PY; Ducimetiere P; Aiach M; Guize L; Consoli SM
    Am J Cardiol; 2006 May; 97(9):1287-91. PubMed ID: 16635597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired release of tissue plasminogen activator from the endothelium in Graves' disease - indicator of endothelial dysfunction and reduced fibrinolytic capacity.
    Li Y; Chen H; Tan J; Wang X; Liang H; Sun X
    Eur J Clin Invest; 1998 Dec; 28(12):1050-4. PubMed ID: 9893018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in plasminogen activator inhibitor 1 and tissue-type plasminogen activator during exercise in patients with coronary artery disease.
    Rydzewski A; Sakata K; Kobayashi A; Yamazaki N; Urano T; Takada Y; Takada A
    Haemostasis; 1990; 20(5):305-12. PubMed ID: 2127039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
    van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
    Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemostatic/fibrinolytic predictors of allograft coronary artery disease after cardiac transplantation.
    Meckel CR; Anderson TJ; Mudge GH; Mitchell RN; Yeung AC; Selwyn AP; Ganz P; Simon DI
    Vasc Med; 1997 Nov; 2(4):306-12. PubMed ID: 9575604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.
    Gürlek A; Bayraktar M; Kirazli S
    Diabetes Care; 2000 Jan; 23(1):88-92. PubMed ID: 10857975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.